NASTAR
Nano-Sensitizer Cancer Cell Targeted Radiotherapy
| Coordinatore | DANMARKS TEKNISKE UNIVERSITET
Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie. |
| Nazionalità Coordinatore | Denmark [DK] |
| Totale costo | 1˙498˙731 € |
| EC contributo | 1˙498˙731 € |
| Programma | FP7-IDEAS-ERC
Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | ERC-2012-StG_20111109 |
| Funding Scheme | ERC-SG |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-04-01 - 2018-03-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
DANMARKS TEKNISKE UNIVERSITET
Organization address
address: Anker Engelundsvej 1, Building 101A contact info |
DK (KONGENS LYNGBY) | hostInstitution | 1˙498˙731.00 |
| 2 |
DANMARKS TEKNISKE UNIVERSITET
Organization address
address: Anker Engelundsvej 1, Building 101A contact info |
DK (KONGENS LYNGBY) | hostInstitution | 1˙498˙731.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Targeted chemotherapy in combination with external beam radiation therapy (radiotherapy) is a promising approach to significantly improve the therapeutic outcome for cancer patients. To achieve this, it is essential to develop drug delivery technology that specifically delivers the chemotherapeutic drugs to cancerous tissue. Radiotherapy is an indispensable part of modern cancer treatment; however, despite efforts in improving planning and execution of treatment, the unbalance between therapeutic benefit and side effects limits cure rates, and new approaches are needed to bring to fruition the full potential of radiotherapy. Today, there is considerable focus on systemically administered radiosensitizers for enhancing the effect of radiotherapy and clinical investigations have shown promising results; however, radiosensitizer use is hampered by considerable side effects due to lack of drug targeting to the cancerous tissue. In the first phase of this project, the aim is to develop tumor targeted nanocarrier delivery systems of radiosensitizers to enhance their therapeutic potential and provide a more efficient and site-directed effect of radiotherapy. In the second phase of the project, nanocarriers for tumor specific delivery of checkpoint inhibitors of cancer cell repair mechanisms will be investigated as an additional targeting strategy for sensitizing cancer cells to radiotherapy. The idea is to circumvent cell cycle checkpoints of DNA damage induced by tumor radiation and thereby enhance mitotic catastrophe. This approach will in combination with the delivery of conventional radiosensitizer drugs, further lower the radiation dose needed to induce irreversible damage to cancer cells. Thus, the project aims to develop targeted nanocarriers for high precision delivery of radiosensitizing drugs to cancerous tissue for enhancing the effect of radiotherapy. We aim to demonstrate the applicability and clinical potential of this new approach within the project period'